Press Release Tryp Therapeutics Announces 99.92% Votes Cast By Shareholders In Favor Of Arrangement Agreement At Annual General And Special Meeting Of Securityholders, And Receipt Of Final Order 14 March 2024
Press Release Tryp Therapeutics And Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX 26 January 20245 May 2024
Press Release Tryp Therapeutics Announces Significant Milestone In Its Clinical Trial Program For Trp[1]8803 (Iv-Infused Psilocin) 8 January 202411 March 2024
Press Release Tryp Therapeutics Announces First Patient Dosed In Phase 2a Clinical Trial For The Treatment Of Fibromyalgia At The University Of Michigan 4 January 202411 March 2024
Press Release Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited 13 December 20237 March 2024
Press Release Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000 20 November 202311 March 2024
Press Release Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million 2 November 202311 March 2024
Press Release Tryp Therapeutics Announces Appointment of CEO and Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000 4 October 202311 March 2024
Press Release Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer 4 August 20236 March 2024
Press Release Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital 13 July 202311 March 2024